For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while pote...

Ausführliche Beschreibung

Bibliographische Detailangaben

1. Verfasser:	Barrenho, Eliana (VerfasserIn)
Weitere Verfasser:	Lopert, Ruth (MitwirkendeR)
Format:	Elektronisch E-Book
Sprache:	English
Veröffentlicht:	Paris OECD Publishing 2022
Schriftenreihe:	OECD Health Working Papers no.146
Schlagworte:	Social Issues/Migration/Health
Online-Zugang:	Volltext
Zusammenfassung:	For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations.
Beschreibung:	1 Online-Ressource (45 p.) 21 x 28cm.
DOI:	10.1787/c9250e17-en